Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Phases › Phase 1

Phase 1 (168 companies)

Companies with at least one active program at Phase 1.

Ticker Company Therapeutic areas Phase 1 programs Lead stage Mkt cap Programs
ABSI Absci DermatologyGI/Hepatology+1 3 Phase 1 $1.75B 6
ACIU AC Immune Neurology Rare 5 Phase 3 $222M 11
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 3 Phase 2 $619M 8
ACRV Acrivon Therapeutics GI/HepatologyOncology Rare 2 Phase 2 $69.0M 9
ACTU Actuate Therapeutics Oncology 2 Phase 2 $7.9M 4
ABOS Acumen Pharmaceuticals Neurology 1 Phase 2 $16.2M 4
ADAG Adagene Oncology 4 Phase 2 $134M 10
ACET Adicet Bio ImmunologyNeurology+2 Rare 7 Phase 1 $28.6M 8
AGIO Agios Pharmaceuticals HematologyMetabolic Rare 2 Approved $1.76B 7
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 1 Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 1 Approved $111M 10
AKTS Aktis Oncology Oncology 10 Phase 1 $880M 10
ALDX Aldeyra Therapeutics DermatologyOncology+1 1 NDA Submitted $38.3M 5
ALLO Allogene Therapeutics ImmunologyOncology Rare 5 Phase 2 $360M 10
DRTS Alpha Tau Medical Oncology 1 Phase 2 $1.27B 6
AMLX Amylyx Pharmaceuticals MetabolicNeurology Rare 1 Phase 3 $3.79B 5
ANTX AN2 Therapeutics HematologyInfectious Disease+1 Rare 3 Phase 2 $151M 6
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 3 Approved $1.39B 9
ANIX Anixa Biosciences Oncology 2 Phase 1 $111M 3
ANNX Annexon HematologyNeurology+2 Rare 2 Phase 3 $796M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 5 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 2 Phase 1 $2.2M 8
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.63B 8
ARVN Arvinas NeurologyOncology Rare 7 Approved $420M 10
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 9 Approved $341M 12
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 4 Phase 2 $2.73B 6
BCAX Bicara Therapeutics Oncology 3 Phase 2 $572M 4
BCYC Bicycle Therapeutics Oncology 1 Phase 2 $253M 4
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 1 Approved $1.98B 4
BMEA Biomea Fusion MetabolicOncology 2 Phase 2 $41.1M 4
BDTX Black Diamond Therapeutics Oncology 1 Phase 2 $99.7M 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $34.5M 8
BBOT BridgeBio Oncology Therapeutics Oncology 6 Phase 1 $164M 6
CCCC C4 Therapeutics Oncology 1 Phase 2 $407M 2
CABA Cabaletta Bio DermatologyImmunology+2 Rare 8 Phase 2 $280M 8
CADL Candel Therapeutics Oncology 1 Phase 3 $670M 4
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $523M 2
RNAC Cartesian Therapeutics ImmunologyNeurology+1 Rare 2 Phase 3 $230M 4
CLDX Celldex Therapeutics DermatologyImmunology+1 2 Phase 3 $2.35B 9
CLRB Cellectar Biosciences Oncology 2 Phase 2 $11.8M 6
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 4 Phase 1 $304M 9
CLYM Climb Bio HematologyImmunology+1 Rare 5 Phase 2 $604M 8
COGT Cogent Biosciences HematologyOncology Rare 2 NDA Submitted $5.51B 7
CHRS Coherus Oncology Oncology 1 Approved $119M 4
CMPX Compass Therapeutics Oncology 13 Phase 2 $137M 15
CGEN Compugen Oncology 2 Phase 3 $186M 7
CTNM Contineum Therapeutics NeurologyRespiratory Rare 1 Phase 2 $374M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $889M 7
COYA Coya Therapeutics Neurology Rare 1 Phase 2 $70.1M 6
CBIO Crescent Biopharma Oncology 8 Phase 2 $503M 10
CRNX Crinetics Pharmaceuticals MetabolicOncology Rare 2 Approved — 6
CUE Cue Biopharma ImmunologyOncology 2 Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 6 NDA Submitted $728M 10
CTMX CytomX Therapeutics Oncology 6 Phase 1 $477M 7
DBVT DBV Technologies Immunology 1 NDA Submitted $3.29B 2
IRON Disc Medicine GI/HepatologyHematology+2 Rare 3 Phase 3 $3.59B 9
EIKN Eikon Therapeutics Oncology 10 Phase 2 $320M 13
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 1 Phase 2 $212M 3
ELTX Elicio Therapeutics Oncology 2 Phase 2 $42.7M 6
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 3 Phase 2 $50.2M 4
ENTA Enanta Pharmaceuticals DermatologyImmunology+1 2 Approved $320M 7
ELVN Enliven Therapeutics Oncology 1 Phase 1 $3.64B 1
ENTX Entera Bio GI/HepatologyMetabolic Rare 1 Phase 2 $547M 4
ERAS Erasca Oncology 2 Phase 1 $5.04B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 1 Approved $1.63B 17
EXEL Exelixis CardiovascularOncology 7 Approved $17.0B 23
FATE Fate Therapeutics ImmunologyOncology+1 Rare 6 Phase 2 $224M 10
FBRX Forte Biosciences DermatologyGI/Hepatology 2 Phase 2 — 3
GANX Gain Therapeutics MetabolicNeurology Rare 1 Phase 1 $45.0M 5
GNLX Genelux Oncology 1 Phase 3 $88.7M 3
GHRS GH Research NeurologyWomen's Health 1 Phase 2 $1.28B 4
HRMY Harmony Biosciences MetabolicNeurology Rare 2 Approved $1.94B 17
IDYA IDEAYA Biosciences Oncology 12 NDA Submitted $3.02B 14
IMTX Immatics Oncology 7 Phase 3 $968M 8
IMMX Immix Biopharma Hematology Rare 1 Phase 1 $577M 1
IMRX Immuneering Oncology 4 Phase 3 $238M 5
IMUX Immunic GI/HepatologyNeurology 1 Phase 3 $106M 4
IBRX ImmunityBio Infectious DiseaseOncology 5 Approved $9.15B 16
IMCR Immunocore DermatologyInfectious Disease+2 9 Approved $1.60B 15
IMNM Immunome Oncology Rare 6 NDA Submitted $2.13B 9
INAB IN8bio ImmunologyOncology 3 Phase 1 $10.0M 4
INBX Inhibrx Biosciences Oncology 3 NDA Submitted $1.24B 6
INSM Insmed CardiovascularImmunology+3 Rare 7 Approved $25.1B 15
IVVD Invivyd Infectious Disease 1 Approved $166M 5
IONS Ionis Pharmaceuticals CardiovascularHematology+5 Rare 2 Approved $6.55B 29
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 $958M 4
JANX Janux Therapeutics Oncology 4 Phase 1 $1.08B 4
KAPA Kairos Pharma Oncology 1 Phase 2 — 13
KZIA Kazia Therapeutics NeurologyOncology Rare 2 Phase 2 $82.0M 13
KROS Keros Therapeutics NeurologyOncology Rare 1 Phase 3 $184M 5
KPRX Kiora Pharmaceuticals Ophthalmology Rare 2 Phase 3 $6.4M 4
KURA Kura Oncology MetabolicOncology 8 Approved $647M 12
KYMR Kymera Therapeutics DermatologyImmunology+1 Rare 2 Phase 2 $11.2B 5
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 2 NDA Submitted $302M 7
LBRX LB Pharmaceuticals Neurology 1 Phase 3 $1.36B 3
LEGN Legend Biotech Oncology Rare 16 Approved $4.55B 17
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 3 Phase 2 $237M 12
LCTX Lineage Cell Therapeutics MetabolicNeurology+1 Rare 1 Phase 2 $258M 12
LQDA Liquidia CardiovascularImmunology+1 Rare 4 Approved $3.97B 9
MAIA MAIA Biotechnology Oncology 1 Phase 3 $64.5M 7
MRKR Marker Therapeutics Oncology 3 Phase 1 $14.8M 4
MAZE Maze Therapeutics MetabolicRenal Rare 1 Phase 2 $1.90B 4
MDNAF Medicenna Therapeutics Oncology 2 Phase 2 $29.5M 10
MGTX MeiraGTx ImmunologyMetabolic+2 Rare 4 Phase 3 $864M 16
MESO Mesoblast CardiovascularGI/Hepatology+2 Rare 2 Approved $1.85B 5
INKT MiNK Therapeutics ImmunologyOncology+1 Rare 2 Phase 2 $52.8M 8
GLUE Monte Rosa Therapeutics CardiovascularDermatology+3 Rare 4 Phase 2 $903M 7
NKTR Nektar Therapeutics DermatologyImmunology+2 1 Phase 3 $1.27B 11
NKTX Nkarta ImmunologyNeurology+1 Rare 8 Phase 1 $124M 8
NBP NovaBridge Biosciences OncologyOphthalmology 4 Phase 2 $106M 7
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $103M 7
NRIX Nurix Therapeutics ImmunologyNeurology+1 8 Phase 3 $1.67B 13
NVCT Nuvectis Pharma HematologyOncology+1 Rare 6 Phase 3 $719M 9
OCGN Ocugen Infectious DiseaseOphthalmology Rare 4 Phase 3 $314M 12
OLMA Olema Pharmaceuticals Oncology 2 Phase 3 $641M 3
OMER Omeros HematologyNeurology+2 Rare 2 Approved $1.22B 6
ONCY Oncolytics Biotech Oncology 1 Phase 2 $56.1M 3
IRD Opus Genetics Ophthalmology Rare 2 Approved $348M 12
ORIC Oric Pharmaceuticals Oncology 2 Phase 3 $914M 5
OVID Ovid Therapeutics Neurology Rare 1 Phase 2 $557M 4
PALI Palisade Bio Immunology 1 Phase 2 $197M 3
KTTA Pasithea Therapeutics NeurologyOncology Rare 2 Phase 1 $19.3M 4
CATX Perspective Therapeutics Oncology 4 Phase 1 $95.9M 4
PHIO Phio Pharmaceuticals Oncology 3 Phase 1 $9.6M 4
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 4 Phase 1 $296M 5
PRLD Prelude Therapeutics HematologyOncology Rare 2 Phase 1 $287M 3
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 3 Phase 2 $5.4M 7
PMN ProMIS Neurosciences Neurology Rare 1 Phase 1 $37.3M 6
PRQR ProQR Therapeutics MetabolicNeurology Rare 2 Phase 1 $191M 7
PTGX Protagonist Therapeutics DermatologyHematology+2 Rare 2 Approved $8.62B 12
RAPP Rapport Therapeutics Neurology 5 Phase 3 $1.45B 10
RXRX Recursion Pharmaceuticals Oncology 2 Phase 2 $2.19B 6
RLAY Relay Therapeutics DermatologyOncology Rare 1 Approved $4.11B 4
RVMD Revolution Medicines Oncology 2 Approved $41.6B 11
RYTM Rhythm Pharmaceuticals Metabolic Rare 2 Approved $7.78B 14
RCKT Rocket Pharmaceuticals CardiovascularImmunology Rare 2 Approved $262M 4
SGMT Sagimet Biosciences DermatologyMetabolic 1 Phase 3 $698M 3
SANA Sana Biotechnology MetabolicOncology 1 Phase 1 $710M 4
SRPT Sarepta Therapeutics NeurologyRespiratory Rare 5 Approved $1.91B 11
SCYX Scynexis Infectious DiseaseRenal Rare 3 Approved $34.8M 5
SEPN Septerna ImmunologyMetabolic+1 Rare 2 Phase 1 $2.28B 5
SION Sionna Therapeutics Respiratory Rare 4 Phase 2 $148M 5
SLDB Solid Biosciences CardiovascularNeurology Rare 2 Phase 3 $736M 6
STOK Stoke Therapeutics Neurology Rare 1 Phase 3 $1.74B 2
GPCR Structure Therapeutics MetabolicRespiratory Rare 2 Phase 3 $4.35B 5
STRO Sutro Biopharma Oncology 2 Phase 1 $160M 4
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $852M 7
TNGX Tango Therapeutics Oncology 4 Phase 1 $3.63B 4
TECX Tectonic Therapeutic Cardiovascular Rare 2 Phase 2 $412M 4
TLX Telix Pharmaceuticals Oncology 7 Approved $3.27B 25
TGTX Tg Therapeutics Neurology Rare 2 Approved $9.16B 6
HURA TuHURA Biosciences Oncology 3 Phase 3 $104M 4
TYRA Tyra Biosciences MetabolicOncology Rare 2 Phase 2 $1.26B 5
UNCY Unicycive Therapeutics Renal 1 NDA Submitted $98.9M 2
QURE uniQure HematologyMetabolic+1 Rare 2 Approved $1.52B 4
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 5 Approved $231M 27
PCVX Vaxcyte Infectious Disease 2 Phase 3 $10.1B 7
VKTX Viking Therapeutics MetabolicNeurology Rare 3 Phase 3 $3.42B 9
VIR Vir Biotechnology Infectious DiseaseOncology Rare 10 Phase 3 $2.09B 12
VRDN Viridian Therapeutics ImmunologyOphthalmology 2 Approved $3.24B 7
VYGR Voyager Therapeutics MetabolicNeurology Rare 2 Phase 1 $116M 9
VTVT vTv Therapeutics HematologyMetabolic+1 Rare 1 Phase 3 $84.4M 9
WVE Wave Life Sciences MetabolicNeurology+1 Rare 3 Phase 2 $665M 5
XNCR Xencor ImmunologyNeurology+1 Rare 21 Approved $2.68B 28
XENE Xenon Pharmaceuticals Neurology Rare 4 NDA Submitted $3.79B 9
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.92B 11
ZURA Zura Bio DermatologyImmunology Rare 1 Phase 2 $394M 5
ZYME Zymeworks OncologyRespiratory 5 Approved $2.10B 11